Filtered By:
Specialty: Cancer & Oncology
Source: Annals of Oncology
Drug: Tamoxifen
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
1366p * risk-benefit index of tamoxifen and raloxifene for chemoprevention of korean breast cancer
Conclusions: Women under the age 40 had more benefit than risk from tamoxifen chemoprevention. In the postmenopausal women with a uterus, raloxifene has more favorable risk-benefit index than tamoxifen.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Chang, M. Tags: prevention and screening Source Type: research
